Prediction aided *in vitro* analysis of octa-decanoic acid from *Cyanobacterium Lyngbya* sp. as a pro-apoptotic factor in eliciting anti-inflammatory properties

Paramasivan Manivannan*, Gangatharan Muralitharan, Nainangu Prasanna Balaji

[1]Department of Microbiology, Bharathidasan University, Tiruchirappalli - 620024, Tamilnadu, India; S.P.Manivannan - E.mail: manivannan3065@gmail.com; Phone: +91 431 2407082 (O); Mobile: +91 9943364520; Fax: +91 431 2407045; *Corresponding Author

Abstract:
Marine Lyngbya has been proven as a potent anticancer agent by disrupting microfilament network. Lyngbya and its associated cyanobacterial compounds have been stressed for futuristic advancements in cancer research and have foreseen explicit advancements in the recent era. Moreover, compounds like lyngbyabellins, lyngbyastatins and other derived toxins are significantly studied. Therefore it is of interest to study the efficacies of Lyngbya fatty acid derivatives. Cytotoxicity and DNA laddering studies proves the efficiency and safety of marine Lyngbya. Caspase – 3 along with MMP2 and MMP9 affirms the anti-inflammatory properties. Molecular docking shows that Octadecanoic acid has strong binding affinity to MMP-2. The role of octadecanoic acid as a proapoptotic factor in emancipation of inflammation apart from inducing apoptosis is of interest to study in future.

Keywords: *Lyngbya*, octadecanoic acid, proapoptotic factor, anti-inflammatory activity, MMP-2, Interaction assessment.

Abbreviation: DNA - Deoxyribonucleic acid, **MMP** - Matrix metalloproteinase, **HPLC** - High performance Liquid Chromatography, **GC-MS** Gas Chromatography Mass Spectrophotometry, **MTT -** (3-[4, 5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide), 5-bromo-4-chloro-3-indolyl-phosphate NBT (nitro blue tetrazolium).

Background:
The arena of natural products research focuses mainly on *Lyngbya* owing to the fact of various secondary metabolites **[1, 2]**, especially pertaining to anticancer research. Marine *Lyngbya* have been a progressive source that has deferred over 260 diversified secondary metabolites contributing a "lion's share" in the field Cyanobacterial metabolites resource (http://www.chem.canterbury.ac.nz/marinlit/marinlit.shtml). Significantly, *L.majuscula* alone is responsible for nearly 196 different secondary metabolites **[3]**. The presence of modular non-ribosomal polyketide synthetase (NRPS) and polyketide synthase (PKS) pathways affirms the biotechnological potentials of *Lyngbya* sp. **[4, 5, 6].** *Lyngbya* has been proven to be an exemplary source in arresting various cancers with varied effects **(Table 1).** Although marine *Lyngbya* has been well denoted as a potent therapeutic, molecular dissection of their anti-inflammatory attribute needs to be unraveled. Several reviews denote the potentiating nature of marine *Lyngbya*, nevertheless

exploitation of this cyanobacterium as a drug modality remains in development and not yet as a commercial commodity. Moreover, In the Indian context, marine *Lyngbya* isolated from Gulf of Mannar has not been reported earlier for its anti-inflammatory activities. In the present study, marine indigenous *Lyngbya* from the Gulf of Mannar was assessed for its anti inflammatory along with anti cancer activities. A comparative study to alleviate the extracellular and intracellular metabolites and their efficacies was noted. Furthermore, *computational* analysis to dissect the mode of action as an anti-inflammatory agent was confirmed through molecular docking to associate the marine *Lyngbya's* rich natural therapeutic property.

Methodology:
Sample Collection:
Cyanobacterial sample was collected from coast of Gulf of Mannar, Rameshwaram, Tamil Nadu, India. The longitude & latitude of location is being identified using GPS locator as N-9°

27 95", E-79° 17 3" **(Figure 1).** The collected samples were collected as three replicate specimens with distance of 3 m for each sample. The samples observed under the microscope and morphologically characterized.

Morphological characterization by microscopy:
The cyanobacterial specimen were observed to be dark green in color, each filaments measures approximately 10 μm in length. They were measured on compound light microscope with a 40x and 10 x ocular lenses with a calibrated optical micrometer. Organism appeared with series of cells surrounded by a tough covering or sheath and mostly long slightly waved. The unbranched filaments are straight, slightly wavy or rarely coiled, and usually form large, layered, leathery mats of varied thickness [7]. The morphology of specimen authenticates for *Lyngbya* sp **(Figure 2).**

Pure culture isolation & mass cultivation:
Lyngbya sp isolate were inoculated in MN solid medium (N+) and incubated at 25oC ± 2oC temperature under controlled light intensity for optimizing growth under laboratory conditions. *Lyngbya* sp was grown in laboratory condition for 12-14 days along with germanium dioxide & cycloheximide to control diatom & green algae contamination. Filaments were picked up selectively and inoculated in to MN liquid media for mass cultivation. Cyanobacterial cultures were initially grown in 250 ml conical flasks MN medium with pH 7.5±0.2 **[8],** followed with 1000ml MN medium for mass cultivation.

Extraction of compounds and HPLC Purification:
Dried biomass (10 grams) of axenic *Lyngbya* sp was grounded with solvent mixture of MeOH: H2O (3:1 V/V) using mortar and pestle and stored at 4oC for 24 hr. Extracts were centrifuged at 10,000 rpm for 15 min and supernatant was collected and stored. Aqueous layer was re-extracted with same solvent twice and extracts were concentrated to dryness in rotary evaporator at (55oC), then concentrated material was extracted with 100% methanol and methanol: water (3:1) separately. Extracts were fractioned in Silica Gel column (1.5 x 20 cm) **[9]** and purified by HPLC system. The active methanolic fraction of column-purified extract was purified further with High performance liquid chromatography. The fraction was detected in reverse phase HPLC ODS-C18 column (4.6mm ID x 25 cm). The mobile phase was mixture of methanol:water of (97:3 to 100 %) added under isocratic conditions. The flow rate was 0.5 ml/min and UV detection performed with 254nm **[10, 11].**

GC/MS analysis of compound:
The GC- MS was performed on Joel, ACCU TOF GCV. The GC coupled with high-resolution mass spectrometer (HRMS) and with library search uses EI ionization mode. About 20 μl samples were injected at 240° C (Injector temperature) in the column (30 m ×0.32 mm ID) with carrier gas as helium. GC oven temperature programme started at 80° C for 2 min followed to final temperature of 280° C. The sample analyzed at constant flow of 2 ml / min. The mass range analyzed at m/z [10 – 600] with ionization detected, recorded using Flame Ionization Detector

(FID). The complete Data acquisition was performed by NIST library search.

DNA extraction:
Total genomic DNA extraction was done as described previously **[12]** and used as a template in PCR reaction. Genomic DNA was extracted from *Lyngbya* sp by following standard procedure **[13].** Eight days old culture was pelleted by centrifugation, then medium was decanted, and the pellet was resuspended in 500 μl of 50 mM Tris-HCL (pH 8.0), 5mM EDTA (pH 8.0), 50 mM Nacl. Lysozyme was added to obtained a final concentration of 1 mg/ml, and the solution was incubated at 55° C for 10 min or until the solution cleared (complete cell lysis). The solution was chilled on ice and extracted with an equal volume of phenol – chloroform-isomylalcohol (25:24:1). Organic extraction was repeated, and the supernatant was added to an equal volume of 4 M ammonium acetate. Total genomic DNA was precipitated by the addition of 2 volumes of isoproponal followed by centrifugation for 10 min at room temperature. Pellet was washed with 70% ethanol, dissolved in TE buffer (10 mMTris- Hcl, 1mM EDTA, and pH 8.0) and stored at -20°C. DNA concentration and purity was measured on a Du 800 Spectrophotometer.

PCR Amplification:
The PCR amplification of DNA with cyanobacterial specific primers was carried out following the protocol of Nubel et al 1997 **[14].** The PCR reaction volumes were 50μl containing 1μl of DNA, 1μl of each primer, 25μl of Taq DNA Master Mix and 22μl of H2O. The PCR reactions were performed in an eppendorf Master Cycler gradient as follows; after initial denaturation at 92^{0}C for 2 min 30 cycles of 92^{0}C for 20s, 52^{0}C for 30s and 72^{0}Cfor 60s. PCR had final extension step at 72^{0}C between 5 to 7min. PCR products were analyzed by electrophoresis in 1.2% agarose gel in 1x TBE buffer stained with ethidium bromide and photographed under UV transilluminator. The sequences of the PCR products were determined by using the BigDye Terminator Cycle Sequencing v2.0 kit on an ABI 310 automatic DNA sequencer (Applied Biosystems, CA, USA).

Cell lines and Cytotoxicity assays:
Cell lines HepG2 and MCF7 were obtained from National Center for Cell Sciences, Pune, India. Cultures were stored in liquid nitrogen, upon usage need they were passaged and thawed for further analysis. The extracts were dissolved in 10% Dimethyl Sulfoxide (DMSO) to give a final concentration of DMSO not more than 0.5% and did not affect cell survival. The viability of cells was assessed by MTT assay using MCF 7 and HepG2 cell lines. The MCF 7 and HepG2 cells were plated separately in 96 well plates at a concentration of 1×10^5 cells/well. After 24 h, cells were washed twice with 100 μl of serum-free medium and starved for an hour at 37oC. After starvation, cells were treated with different concentrations of extract (25-200μg/ml) for 24 h. At the end of the treatment period the medium was aspirated and serum free medium containing MTT (0.5 mg/ml) was added and incubated for 4 h at 37oC in a CO2 incubator. The 50% inhibitory concentration value (IC$_{50}$) of the crude extracts was identified. The MTT containing medium was then discarded and the cells were washed with PBS (200 μl). The crystals were then dissolved

by adding 100 µl of DMSO and this was mixed properly by pipettting up and down. Spectrophotometrical absorbance of the purple blue formazan dye was measured in a microplate reader at 570 nm (BIORAD 680). Cytotoxicity was determined using Graph pad prism5 software.

DNA Fragmentation:

In 24 flat-wells plate, 2x10^5 MCF 7 and HepG-2 cells (triplicate wells of 10^5 per well) were incubated with different concentration of sample (25- 200) (10^5 target cells per well). Fresh DMEM medium was added and incubated for 24 hours, cell sample was collected in 1.5 ml eppendorf tube, spinned down, resuspended with 0.5 ml PBS in 1.5 ml eppendorf tubes, and 55ul of lysis buffer (40 ml of 0.5 M EDTA 5 ml of 1 M TrisCl buffer pH 8.0 5 ml of 100% Triton X-100 50 ml of H$_2$O) was added and kept in ice for 20 min (4°C). After centrifugation in cold at 12,000 g for 30 minutes, the samples were transfered to new 1.5 ml eppendorf tubes and then the supernatant was extracted with 1:1 mixture of phenol: chloroform (gentle agitation for 5 min followed by centrifugation) and precipitated in two equivalence of cold ethanol and one-tenth equivalence of sodium acetate. Then the precipitates were resuspended in 30ul of deionized water-RNase solution (0.4ml water + 5ul of RNase) and 5ul of loading buffer for 30 minutes at 37°C. After agarose gel electrophoresis, the image was observed for DNA shearing in 312nm UV illuminator.

In vitro activity:

Western Blotting:

Protein expression was determined on the cytosolic extracts from treated cells using western blotting. The cytosolic protein samples were isolated and quantified using Bradford assay and kept at 80°C until use. The protein samples (25µg/well) were electrophoresed by using 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF membrane. Immunoblot analysis was carried out using rabbit anti-rat polyclonal antibody (1:1000) as primary antibody and alkaline phosphatase-conjugated goat anti-rabbit IgG (1:5000) as secondary antibodies, respectively. Target protein was detected using alkaline phosphatase and NBT-BCIP as the substrate. The band intensity was measured densitometrically using Image J software. Briefly, the method consisted of analyzing the integrated densities (the area of the particular band multiplied by the mean value) of individual bands of the scanned blot. β- actin was used to normalize the target and the relative expression was stated as fold ratio.

Table 1. Notable anticancer compounds from *Lyngbya*

Compounds	Source	Mode of action
Curacin A	Lyngbya majuscula	Inhibition of microtubule assembly
Dolastatin 15, Cematodin (LU-103793), ILX-651 (Synthadotin)	Lyngbya sp.	Breast cancer abatement
Apratoxin A	Lyngbya sp.	Efficient in arresting early stage adenocarcinoma
Somocystinamide	Lyngbya	Cyto toxicity against mouse
A	majuscula/	neuro-2a neuroblastoma
	Schizothrix sp. Assemblage	cells
Lyngbic acid and malyngamide C	L. majuscula	Cytotoxic against HT29 colon cancer
Apratoxin D	L. majuscula and L. sordida	Cancer cell toxicity
Apratoxin E,	L. bouillonii	Cytotoxicity
Caylobolide A	L. majuscula	In vitro cytotoxicity against human colon tumor cells
Lyngbyaloside	L. bouillonii	
Lyngbyabellin J, laingolide B, lyngbyapeptin D, lyngbyabellins A and B, lyngbyapeptin A, and lyngbyaloside	L. bouillonii	Cytotoxicity
Curacins B and C	L. bouillonii	Cytotoxicity against murine L-1210 leukemia and human CA46 Burkitt lymphoma cell lines
Itralamide B	L. majuscula	Cytotoxicity against human embryonic kidney (HEK293)
Hantupeptin A	L. majuscula	Cytotoxicity to MOLT-4 leukemia cells and MCF-7 breast cancer cells
Lyngbyabellin A	L. majuscula	Disruption of cellular microfilament network
Lagunamides A and B	L. majuscula	Cytotoxic activity against P388 murine leukemia cell lines
Lynbyabellin E-I	L. majuscule	Cytotoxicity to human lung, tumor and neurobalstoma cell lines.

Figure 1: Depicts the sampling site mandapam in the Gulf of Mannar region with accurate eight latitude and longitude.


Figure 2: The MTT assay profiles indicating high cytotoxicity of aqueous extracts of 5 *Lyngbya* sp against HepG2 and MCF cell lines.

Computational studies:
Active site prediction and preparation of ligands:
Ligand binding sites were predicted using Qsite finder (http://www.modelling.leeds.ac.uk/qsitefinder/), surface topology and pocket information were analyzed by theCASTp server (http://stsfw.bioengr.uic.edu/castp/calculation). The results were compared to PDB sum records. The solvent accessible surface area (SASA) was found employing GETAREA (http://curie.utmb.edu/getarea.html). The atomic SASA covered by each cleft was calculated by utilizing radius of water probe 1.4 A°, and the area/energy/residue was calculated. Dielectric constant was set to 80.0, and Poisson–Boltzman method of computation for 20 cycles was used for calculating the

electrostatic potential. Ligands namely, rhodopin and octadecanoic acid as obtained by GC-MS analysis was retrieved from the PUBCHEM database (https://pubchem.ncbi.nlm.nih.gov/search/search.cgi) in their canonical SMILES format. Files were then converted into PDB files using openbabel.


Figure 3: Demonstrates the anti inflammatory profiles of intracellular and extracellular 4 extracts of *Lyngbya* sp with high fold ratio for extracellular extracts showing its 5 therapeutic profile.


Figure 4: Contrarily shows that intracellular extracts possess high DNA fragmentation 4 activities.

Target receptors and docking analysis:
MMP 2 and MMP 9 were chosen for the present analysis. The structures were retrieved from Protein Data Bank (http://www.rcsb.org/pdb) with PDB ID: 1ITV and 1RTG. Solvent accessibility was utilized as a criterion in emancipating the binding nature of the peptides. ASAVIEW [15] was used for Solvent accessibility calculations. The online docking program

©2017

PATCHDOCK [http://bioinfo3d.cs.tau.ac.il/PatchDock/] was used for rigid docking of the proteins with rhodopin and octadecanoic acid. Ligand interactions were analyzed by Discovery studio (http://accelrys.com/products/discovery-studio/visualization-download.php) and were viewed with PYMOL.

Results and Discussion:

Metabolites involved in Bioactivity:

Cyanobacteria continue to be a significant source of compounds that show unprecedented biological activities of pharmaceutical thrust. Cyanobacterial metabolites prove to possess a wide range of biological activities ranging from anti-microbial and immunosuppressant to anti-cancer and anti-HIV. **Figures 3 and 4** depict the location map and microscopic images of *Lyngbya* sp. Surprisingly, Intracellular extract showed significant cytotoxicity and DNA laddering patterns, whereas, extracellular extract illustrates the protein expression differentially in caspases-3, MMP-2 and MMP-9 activities. GC-MS analysis revealed the presence of two principal components namely rhodopin and octadecanoic acid, 3-Hydroxy-2-tetradecyl-methylester **(Figure 3)**. Unsaturated fatty acids have long been proposed for antimicrobial nature. Furthermore, pharmaceutical properties of activities α-linolenic acid are well known **[16]**. With regard to anticancer activity, linoleic and α-Linolenic acids have been accounted to possess prominent proapoptotic effects and growth inhibitory roles **[17]**. Although antimicrobial nature of octadecanoic acid has been well documented, their exact role in anticancer and anti inflammatory properties have not been thoroughly studied. The present work is first of its kind in addressing *Lyngbya* sp. as an anti-inflammatory agent and the key component as octadecanoic acid.


Figure 5: Indicates the hydrogen bond donor ARG133 with varied hydrogen acceptors.

In vitro activity:

200 uL aqueous extracts of Lyngbya sp. show efficient cytotoxicity by MTT assay **(Figure 4)**. The active principles from the aqueous extracts were primarily found to be octadecanoic acid and rhodopin. Previous studies with Terminalia belerica methanolic extracts (TBME) were found to possess phenolics, flavonoids, and other phytochemicals, which render TBME to involve in anticancer activity. Reserpine, tannic acid, quercetin, catechin, and gallic acid/ascorbic acid were found to be active ingredients through HPLC analysis. Cytotoxicity of TBME was demonstrated against A549 and MCF7 cell lines significantly. The cytotoxicity was presumed to be the effector processes of apoptosis, necrosis or cell cycle arrest **[18]**. Furthermore wild-type p53 upregulation of Bax and downregulation of Bcl-2 that results in apoptosis was categorized as the principle process involved **[19, 20]**. In the present study, MTT Assay depicts the intracellular extract as the predominant source for cytotoxicity and DNA fragmentation affirms the phenomenon. Till date, there have been ample reports on plants that exhibit both anti-cancer and anti-inflammatory activities. But cyanobacteria in eliciting this response are scarce.

Western Blotting:

Apoptosis of extracts in general have been regarded as a resultant of Bax/Bcl-2 ratio that leads to cytochrome c release that indeed results in caspase activation to be proceeded as apoptosis through the mitochondrial pathway **[21, 22]**. Proapoptotic nature of octadecanoic acid might be attributed to cleavage of caspase-3 **[23]**. Blotting of the treated cell lines revealed the presence of caspase 3 (35 KDa), MMP2 (72 KDa) and MMP9 (92 KDa). The results of blotting clearly indicate the effect of active principles of extracts on the expression profiles of cell lines HepG2 and MCF7 **(Figure 5)**. HepG2 cell line activity can be corroborated with hepatoprotective nature of octadecanoic acid. Free fatty acids exposure over a period of time has implications on reduced glucose stimulated insulin secretion and apoptosis of human pancreatic cells. Proapoptotic effects in this regard were not affirmed through caspases whereas dependent on ceramide pathway and Bcl-2 regulation might possibly have its role **[23]**. Positive effects of octadecanoic acid methyl ester against breast cancer inhibition might be due to arrest of *de novo* Diacylglycerol synthesis that induces apoptosis of human breast cancer cells. Activated Phosphokinase C reversed caspase-3 activation might be a modality of inhibition of breast cancer development **[24]**. Hence octadecanoic acid might have its effect on MMP2 and MMP9 through caspase3 activation and inflammation, leading to apoptotic cell death. Interestingly, extracellular extracts of *Lyngbya* sp. show high fold percentage of Caspase-3, MMP2 and MMP9 when compared to intracellular extract. DNA fragmentation profiles of the aqueous extracts clearly establish *Lyngbya* to be a potent anti cancer repertoire**.** Comparatively, extracellular extracts show increased bioactivity. Hence, the present analysis explains that both intracellular and extracellular extracts as a drug modality in combating inflammatory nature of *Lyngbya* sp.

Computational studies:

Figure 5 depicts efficient interaction between Octadecanoic acid – MMP2 (-137.63 KJ/mol) than MMP9 (-121.55 KJ/mol). However its efficacy in interaction with caspase3 (-218.89 KJ/mol) is twofold than MMP's indicating high anticancer activities prior to anti inflammatory activities and western blotting results affirm this phenomenon. Hydrophobic interactions between ARG133 render catalytic residues occupied with octadecanoic acid**.** Similarly, it was earlier proposed that n-hexadecanoic acid in the channel of the enzyme hampered the substrate entry and HIS 48, ASP 49, and a catalytic Ca2+ were found unavailable to the substrate. Further, computational studies showed that n-hexadecanoic acid had a binding energy of 58.14 Kcal ∕ mol when compared to the present study with -137.63 KJ/mol. Binding in roller coaster rail model was also seen as in the previous studies **[25,26].** Hence there is a dire need in studying bioactive nature of cyanobacteria and cyanobacterial natural product chemistry still remains underexploited. Nevertheless there have been several limitations and lacunae in addressing bioinformatics potentials for efficient identification and betterment of human health perspective.

Conclusions:

Extracellular extract of *Lyngbya* sp. show potent anti-inflammatory property. Which is evident from their fold percentage in Protein expression showing anti-inflammatory nature by western blotting. *Computational* results also corroborates by increased binding affinities to Caspase 3, MMP2 and MMP9. HPLC and GC MS confirm the presence of rhodopin and octadecanoic acid as the active principles in eliciting anti-inflammatory along with anti-cancer properties. Among which, octadecanoic acid promisingly binds to MMP2 implicating role as a proapoptotic factor. However, further interior research is needed to emancipate octadecanoic acid's role in apoptosis.

Acknowledgement:

Conflict of interest:

The Authors declare that they have no competing interests.

References:
[1] Gerwick WH *et al.* Microbe 2008 **3:** 277-284.
[2] Tidgewell K *et al.* The natural products chemistry of cyanobacteria. Oxford: Pergamon Press. 2010
[3] Engene N *et al.* Environ Microbiol. 2011 **13:**1601 [PMID 21477107]
[4] Soria-Mercado IE *et al.* Organic letters. 4704 [PMID: 19754100]
[5] Sharp K *et al.* Appl. Environ. Microbiol. 2009 2879. [PMID: 19270119]
[6] Moore RE. J Indust. Microbiol. 1996 **16:**134. [PMID: 8730577]
[7] Desikachary TV. In Cyanophyta. (Indian Council of Agricultural Research, New Delhi, India). 1959
[8] Littler DS & Littler MM. 2000 542.
[9] Semary NAE. Ann Microbiol. 2012 **62:**55.
[10] Jaffe GM. Ascorbic acid. In: Grayson M (ed) Kirk-Othmer encyclopedia of chemical technology. Wiley, New York. 24
[11] CJ *et al.* Mar. Drugs. 2009 **7:**528 [PMID: 20098596]
[12] Neilan BA. Appl. Environ. Microbiol. 1995 **61:**2286. [PMID: 16535049]
[13] Smoker JA and Barnum SR. FEMS microbiology letters, 1998 **56:**119
[14] Nübel U *et al.* Applied and Environmental Microbiology. 1997 63:3327 [PMID: 9251225]
[15] Ahmad S *et al.* BMC Bioinformatics. 2004 **5:**51 [PMID: 15119964]
[16] Mundt S *et al.* Int. J. Hygiene Environ. Health. 2001 **203:**327
[17] Ringbom T *et al.* J Nat. Prod. 2001 **64:**745 [PMID: 11421736]
[18] Chan WM *et al.* Mol Cancer Res 2006 **4:**15 [PMID: 16446403]
[19] Miyashita T & Reed JC. Cell 1995 **80:**293 [PMID: 7834749]
[20] Meenakshii N *et al.* J Trop Med Plants. 2000 **1:**1.
[21] Park MT *et al.* Clin Cancer Res 2003 **9:**878 [PMID: 12576463]
[22] Ghate NB *et al.* Cytotechnology. 2014 **66:**209 [PMID: 23686547]
[23] Lupi R *et al.* Diabetes. 2002 **51:**1437. [PMID: 11978640]
[24] Aparna M *et al.* Int. J. of Biolog and Pharma. Res. 2012 **3:**631.
[25] Agoramoorthy M *et al.* Braz J Microbiol. 2007 **38:**739.
[26] Yu Y *et al.* Biochim Biophys Acta. 2002 **1581:**89 [PMID: 12020636]